Le Lézard
Classified in: Science and technology
Subject: PER

DQLabs Appoints Dave Casillo as Chief Revenue Officer to Drive Strategic Growth


PASADENA, Calif., April 18, 2024 /PRNewswire/ -- DQLabs, a leading SaaS modern data quality platform provider, today announced that Dave Casillo has joined the DQLabs leadership team as its first Chief Revenue Officer. This executive level go-to-market appointment signals the next stage in DQLabs' rapid growth journey.

Dave is a proven senior executive with more than 37 years of business experience in diversified global businesses including 25 years in the IT industry. He has a very strong background leading both Fortune 500, as well as early-stage sales organizations in the enterprise software space. Dave has established a strong reputation for driving both direct and indirect sales growth, building world class sales teams, growing partnerships, driving process efficiency and scaling businesses. 

Casillo most recently held the Chief Revenue Officer role at Congruity360, a SaaS based software company dedicated to unstructured data management with a focus on data classification, governance, and compliance. Prior to that role, Dave was the CRO of Erwin where he helped lead the revenue growth of the structured data governance & modeling company culminating in a successful acquisition by Quest Software.

He has been a key member of senior management teams for Hewlett Packard Enterprise, Dolby Laboratories, Adobe Systems, Insight Enterprises and Arrow Electronics. He has held multiple Chief Revenue Officer, SVP Channels & Alliances and Chief Marketing Officer positions during his career. He is also a member of a very exclusive group of channel veterans who have been an executive leader at a software vendor, solution provider and distributor.

Dave holds a BS and MBA from Drexel University and is a graduate of the General Management Program at Harvard Business School. 

"Dave's hiring will be instrumental in our mission to achieve our strategic goals and vision for the future. He is a consummate professional who has the necessary skills, experience, and knowledge to drive our company's go-to-market efforts," said Raj Joseph, Founder & CEO of DQLabs. "Dave is an outstanding addition to our rapidly growing senior leadership team."

About DQLabs
DQLabs is an automated Modern Data Quality platform that delivers reliable and accurate data for better business outcomes. DQLabs automates quality and observability checks and resolution by harnessing the combined power of Data Observability and Data Quality powered by Semantics and GenAI to deliver "fit-for-purpose" data for consumption across reporting and analytics.

For more information visit: https://www.dqlabs.ai 
Contact:
Raj Joseph
Founder & CEO, DQLabs, Inc
[email protected] 
720-256-7540

SOURCE DQLabs, Inc.


These press releases may also interest you

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: